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Mutations in the FKRP gene are associated with a wide 
range of muscular dystrophies from mild limb-girdle 
muscular dystrophy (LGMD) 2I to severe Walker– 
Warburg syndrome and muscle-eye-brain disease. The 
characteristic biochemical feature of these diseases is 
the hypoglycosylation of α-dystroglycan (α-DG). Cur-
rently there is no effective treatment available. In this 
study, we examined the adeno-associated virus serotype 
9 vector (AAV9)-mediated gene therapy in the FKRP 
mutant mouse model with a proline to leucine missense 
mutation (P448L). Our results showed that intraperito-
neal administration of AAV9-FKRP resulted in systemic 
FKRP expression in all striated muscles examined with 
the highest levels in cardiac muscle. Consistent with our 
previous observations, FKRP protein is localized in the 
Golgi apparatus in myofibers. Expression of FKRP conse-
quently restored functional glycosylation of α-DG in the 
skeletal and cardiac muscles. Significant improvement in 
dystrophic pathology, serum creatine kinase levels and 
muscle function was observed. Only limited FKRP trans-
gene expression was detected in kidney and liver with 
no detectable toxicity. Our results provided evidence for 
the utility of AAV-mediated gene replacement therapy 
for FKRP-related muscular dystrophies.
Received 23 August 2012; accepted 23 June 2013; advance online  
publication 30 July 2013. doi:10.1038/mt.2013.156
INTRODUCTION
The Fukutin-related protein (FKRP) gene encodes a predicted 
type II membrane protein consisting of a hydrophobic N-terminal 
transmembrane domain, a stem region, and a putative catalytic 
C-terminal domain with a D×D motif, a conserved structure 
found in many glycotransferases.1 FKRP mutations are associ-
ated with muscular dystrophies of highly variable clinical severity, 
ranging from common and milder limb-girdle muscular dystro-
phy (LGMD2I), to severe forms of congenital muscular dystrophy 
(MDC1C) with or without involvement of central nervous sys-
tem, Walker–Warburg syndrome and muscle-eye-brain disease.2–5 
These diseases share a common biochemical defect in the gly-
cosylation of α-dystroglycan (α-DG) in muscle tissues com-
monly referred to as dystroglycanopathies. Other genes involved 
in dystroglycanopathies include fukutin, POMGnT1, POMT1, 
POMT2, and LARGE.6 There is an evidence that POMT1, 
POMT2, and POMGnT are able to initiate the first two steps of 
a unique O-mannosylation pathway of glycosylation to α-DG.7,8 
More recently, LARGE has been shown to act as a bifunctional 
glycosyltransferase, that has both xylosyltransferase and glucuro-
nyltransferase activities, producing repeating units of [–3-xylose–
α1,3-glucuronic acid-β1–].9 However, the function of both 
fukutin and FKRP in the glycosylation of α-DG remain elusive.
α-DG is a central component of the dystrophin-associated 
glycoprotein complex, linking the actin cytoskeleton of the muscle 
fibers with extracellular ligands, such as laminin α2, perlecan, big-
lycan, neurexin, and agrin. This linkage is important for the integ-
rity of the muscle fiber structure.10–12 The function of α-DG and 
its interaction with extracellular matrix proteins largely depends 
on O-linked glycosylation in the mucin-like domain.10,13 Defective 
α-DG glycosylation as the result of FKRP mutations is thought 
to lead to disruption of the linkage between the subsarcolemmal 
cytoskeleton and the extracellular matrix, which in turn leads to 
muscle degeneration. In addition, functionally glycosylated α-DG 
plays an important role in the development of the central nervous 
system.14,15
Currently there is no effective treatment for FKRP-related 
diseases. Over the past decades, adeno-associated virus (AAV)-
mediated gene therapy has been extensively investigated in differ-
ent disease models and has emerged as one of the most promising 
approaches as a delivery vector, owing to its high tropism for skel-
etal and cardiac muscles and nonpathogenicity in humans.16–22 
Several AAV serotypes have been tested in preclinical studies 
with long-term success in targeting muscles through a systemic 
approach.17–19 New progress in clinic trials for sarcoglycan defi-
cient LGMD2D, LGMD2C and other diseases has offered realistic 
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hope for AAV vector-mediated gene therapy to achieve therapeu-
tic results in the clinics.23–25
Cardiomyopathy is a common feature in FKRP-related mus-
cular dystrophies and becomes an increasingly important consid-
eration for treatment development. Cardiac involvement includes 
dilated cardiomyopathy,26 focal myocardial fibrosis,27 and car-
diac failure.26,28,29 The severity of cardiac disease, however, may 
not be related to the severity of skeletal muscle involvement.30 
Exploration and optimization of AAV serotypes have also led to 
the identification of highly effective AAV serotypes with cardiac 
muscle tropism permitting effective delivery of therapeutic trans-
gene to affected cardiac muscles.20–22 Among the AAV serotypes, 
AAV9 has higher tropism to cardiac muscle, thus could be the 
choice for treating FKRP-related cardiomyopathy.20,21
Recently we have created mouse models containing reported 
FKRP mutations in patients with LGMD2I and MDC1C. Our 
analyses showed that knock-out of the FKRP was embryonic 
lethal. Knock-in of different missense mutations including P448L 
resulted in muscular dystrophy with variable severity ranging 
from early death to a mild dystrophic phenotype with later onset 
of muscle degeneration.31 These observations provide direct evi-
dence to support the important role of FKRP in glycosylation of 
α-DG and correlation between genotype and phenotypic varia-
tions in clinics. These mouse models are also valuable for devel-
oping and testing experimental therapies for the diseases. In this 
study, we examined the efficacy of AAV9-mediated FKRP gene 
therapy in the P448L mutant mice. While the heterozygotes of 
the P448L mutation are phenotypically normal, the homozygotes 
showed lack of functional glycosylated α-DG and early disease 
onset (around 3–4 weeks of age) with prominent muscle pathol-
ogy and impaired skeletal muscle functions. Here we show that 
systemic delivery of AAV9-FKRP at the age of 3–4 weeks produced 
high levels of FKRP expression in all skeletal muscles examined, 
and most prominently, in the cardiac muscle. This was associated 
with the restoration of functional glycosylation of α-DG up to 
near normal levels in cardiac muscle, amelioration of the skeletal 
muscle pathology, and significantly improved function. The treat-
ment did not cause detectable toxicity in the liver or kidney. Our 
study indicates that AAV9-mediated gene therapy represents an 
effective strategy for FKRP-related muscular dystrophy.
ResUlTs
AAV vector construction and in vitro verification of 
FKRP expression
The AAV9 vector and chicken β-actin promoter coupled with the 
CMV enhancer (referred to as CMV-CB promoter) was used for 
effective transgene expression.18 The mouse Fkrp coding sequence 
was codon-optimized for high expression (Supplementary 
Figure S1, online). The AAV9-CMV-CB-FKRP vector (referred 
to as AAV9-FKRP) was initially examined in C2C12 myoblasts 
and differentiated myotubes. Strong expression of FKRP was 
detected by immunofluorescence staining with the antibody 
FKRP829 (also called FKRPSTEM). The strongest signals in the 
myoblasts were localized in the peri-nuclear areas although weak 
punctate signals were also found in other parts of the cytoplasm 
(Figure 1a). Consistent with our previous observation with plas-
mid-mediated FKRP expression and recent findings in human 
rectus muscle tissue,32,33 these signals colocalized with GM130, 
a cis-Golgi marker. In differentiating myotubes, FKRP stain-
ing appeared as punctate dots within the entire cytoplasm and 
surrounding the nuclei where the signals also colocalized with 
GM130 (Figure 1b). Colocalization of the Myc-tagged FKRP 
and GM130 was confirmed by double staining (Supplementary 
Figure S2, online).
FKRP expression and localization in skeletal muscle 
by local injection
We next examined the AAV9-FKRP expression in skeletal muscle 
by intramuscular injection of 5 × 1010 vector genomes (v.g.) into 
tibialis anterior (TA) muscle of the P448L mutant mice aged 4–6 
weeks. In the untreated mice, functionally glycosylated α-DG was 
barely detectable in the muscles by both immunostaining and 
western blot. One week after vector injection, strong FKRP expres-
sion was detected with the FKRPSTEM antibody in the majority 
of myofibers of the injected muscle. FKRP immunoreactivity was 
detected in an array of puncta regularly distributed within the sar-
coplasm. A high number of puncta with relatively stronger signals 
were also detected near the sarcolemma (Figure 2). The polyclonal 
antibody to Myc-tag revealed the same patterns as those detected by 
the FKRPSTEM antibody. Consistent with our earlier observation, 
Figure 1  FKRP expression in C2C12 myoblasts (a) and a single myo-
tube (b) detected by immunocytochemistry with the antibodies to 
FKRP (red signal) and the Golgi marker GM130 (green signal). The 
two signals colocalize with close proximity (Merged). Blue, DAPI nuclear 
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the signals either overlapped or closely colocalized with the signal 
of GM130 in the cis-Golgi apparatus (Figure 2). A few fibers with 
FKRP immunoreactivity throughout the entire sarcoplasm were 
also detected (Supplementary Figure S3, online). Endogenous 
FKRP was not detected by the antibody. Expression of FKRP was 
confirmed by western blot (Figure 3). No signal representing 
endogenous FKRP was clearly detected in the muscles of untreated 
animals (Supplementary Figure S3, online). In contrast to the 
controls, the treated muscles of FKRP mutant mice showed strong 
signals with the IIH6 antibody that recognizes functionally glyco-
sylated α-DG (Figure 2). These results indicate that FKRP expres-
sion by AAV-9 mediated gene delivery is able to restore functional 
glycosylation of α-DG in muscles.
systemic treatment with AAV9-FKRP restores 
functional α-dystroglycan in all skeletal muscles 
examined
We next examined the systemic effect of AAV9-FKRP treatment by 
intraperitoneal (i.p.) injection to the P448L mutant mice aged 3–4 
weeks. The mice were given a single dose of 5 × 1011 v.g. and exam-
ined 4 months later. FKRP expression was first assessed by immu-
nostaining (Figure 3a). Skeletal muscles including TA, quadriceps, 
gastrocnemius, and diaphragm, all showed relatively homoge-
neous expression of the FKRP protein in the majority of muscle 
fibers detected with the FKRPSTEM antibody. These results were 
confirmed with the rabbit antibody against Myc-tag. Similar to the 
patterns observed in the TA muscles after local treatment, FKRP 
formed small puncta that predominantly localized near to, but 
not in the sarcolemma. Once again, the signals of FKRP colocal-
ized well with the signal of GM130. A variable proportion (less 
than 15%) of myofibers in all muscles was found without clearly 
detectable signal for FKRP expression (Supplementary Figure S4, 
online). Sporadically, myofibers (less than 1%) with FKRP overex-
pression covering the entire cytoplasm were also observed in all 
muscles. Variation of FKRP expression in different muscles was 
demonstrated by western blots (Figure 3b). FKRP expression was 
generally higher in the diaphragm than those in the other skeletal 
muscles, likely due to the i.p. delivery route which allows a direct 
contact of the diaphragm with the viral vectors.
FKRP expression correlated well with the levels of functionally 
glycosylated α-DG in the AAV9-FKRP treated mice. To compare 
the levels of FKRP expression to those of functionally glycosyl-
ated α-DG within the same myofibers, serial sections were stained 
with both IIH6 and FKRPSTEM antibodies. Nearly all fibers that 
showed detectable levels of FKRP expression were stained clearly 
with IIH6 antibody as well (Figure 3, Supplementary Figure S4, 
online). By contrast, most myofibers without detectable FKRP 
displayed little to no signals with the IIH6. A few IIH6-positive 
fibers without detectable FKRP expression were also observed. 
However, such fibers were also detected in untreated FKRP 
mutant mice (Supplementary Figure S4, online). Signal intensity 
for functionally glycosylated α-DG was not higher in the fibers 
with strong FKRP signal covering the entire cytoplasm than that 
in the majority of myofibers containing only punctate signals for 
FKRP. This suggests that highly overexpressed FKRP could not 
further enhance the functional glycosylation of α-DG. The overall 
levels of functionally glycosylated α-DG detected by western blots 
ranged from 30 to 70% of normal levels with the higher levels 
detected in the diaphragm (Figure 3b). The functionality of the 
α-DG was supported by a laminin binding assay with intensity of 
immunoreactivity similar to that in normal muscle (Figure 3c).
FKRP expression significantly improves skeletal 
muscle pathology and functions
Restoration of high levels of functional α-DG 4 months after 
AAV9-FKRP treatment unambiguously improved pathology in 
all skeletal muscles examined. Histological evaluation by hema-
toxylin and eosin (H&E) staining showed that muscle fibers 
Figure 2 FKRP expression and functional glycosylation of α-DG in tibialis anterior (TA) muscle of the P448l mutant mice after AAV-FKRP 
treatment. Upper panel: FKRP was detected with the FKRPSTEM antibody (left) and the Golgi apparatus detected with antibody GM130 (middle). 
Merged is the overlay of FKRPSTEM with GM130 (right). Lower panel: FKRP was detected with the FKRPSTEM (left) and functionally glycosylated 
α-DG detected with the IIH6 (middle). Control, TA muscle from untreated control P448L mutant mouse stained with IIH6 (right). Blue, DAPI nuclear 
staining. Scale bar, 60 µm.
FKRPSTEM GM130 Merged
FKRPSTEM IIH6 Control
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(>95%) were highly uniform in size. Small regenerating myofibers 
with diameters less than 30 µm became rare (less than 3%) in the 
treated muscles whereas up to 25% was detected in the controls 
(Figure 4). At the same time, hypertrophic fibers (with sizes larger 
than normal fibers of the equivalent muscle) decreased in AAV-
FKRP treated samples when compared with the untreated FKRP 
mutant mice (Supplementary Figure S5, online). Myofibers with 
central nucleation (a marker of muscle degeneration and regen-
eration) were significantly reduced (less than 15%) in all muscles 
of the treated mice compared with the control muscles (greater 
than 60%). Focal muscle degeneration and infiltrations were fre-
quently observed in the untreated control muscles, but absent in 
the treated muscles (Figure 4, Supplementary Figure S6, online). 
Improvement in muscle pathology was most conspicuous in the 
diaphragm. The untreated P448L mutant mice showed large areas 
of muscle degeneration and regeneration with groups of small-cal-
iber fibers and mononucleate infiltrates in the extracellular matrix 
(Figure 4a). By contrast, the diaphragms of AAV9-FKRP treated 
mice were highly homogeneous in fiber size with little infiltrate 
as shown in Figure 4a. The percentage of central-nucleated fibers 
was also reduced significantly from greater than 50% in the con-
trol samples to less than 5% in the treated samples (Figure 4b).
We also evaluated skeletal muscle function with grip force 
tests. Both the forelimb and hindlimb maximum grip force 
strength showed significant improvement in the AAV9-FKRP 
treated P448L mutant mice, reaching 80 and 90% normal 
 levels (C57 mice as 100%) whereas the force was within 70 and 
Figure 3 expression of FKRP and functionally glycosylated α-DG. (a) Expression of FKRP and functionally glycosylated α-DG detected with 
antibody FKRPSTEM (upper panel, red) and IIH6 (lower panel, green) respectively, after AAV9-FKRP treatment. Untreated, muscles from untreated 
FKRP mutant mice. C57BL/6 (Normal), cardiac muscle. Treated, muscles from AAV9-FKRP treated FKRP mutant mice. Scale bar, 60 µm. (b) 
Detection of FKRP expression and functionally glycosylated α-DG by western blots with IIH6 and laminin binding (LB) assay in AAV9-FKRP (AAV) 
treated P448L mutant mice. Lanes: B, brain; D, diaphragm; H, heart; G, gastrocnemius; T, tibialis anterior; CH, heart from control P448L mutant 
mouse; W, cardiac muscles from wild-type control C57BL/6 mice; TA, tibialis anterior muscle after local injection of AAV9-FKRP. *Nonspecific pro-
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Figure 4  Histological analysis of muscle tissues. (a) Histological 
analysis of muscle tissues from control P448L mutant (upper panel) 
and AAV9-FKRP treated P448L mutant mice (lower panel). Hematoxylin 
and Eosin (H&E) staining. (b) Percentage of centrally nucleated fibers 
(CNF) (left panel) and percentage of regenerating fibers (RF) with 
small calibers (≤30 µm in diameter; right panel). n = 5, *Significant, 
two-tailed t-test, *P ≤ 0.05. Scale bar, 60 µm. Dia, diaphram; Gas, 
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75% normal levels in the untreated mutant mice, respectively 
(Figure 5a, b). Improved muscle functions was strongly sup-
ported by a significant reduction in serum levels of creatine 
kinase, with average of 700 U/l compared with above 4,000 U/l 
in the untreated group (Figure 5c).
High levels of FKRP expression and functional 
glycosylation of α-DG in cardiac muscle
P448L mutant mice also lack functional glycosylated α-DG in 
cardiac muscle. As expected, AAV9-CMV-CB vector achieved a 
higher FKRP expression in the cardiac muscle when compared 
with that of the skeletal muscles. More than 95% of cardiac muscle 
fibers showed strong punctate signals for FKRP detected by anti-
bodies to both FKRP and the Myc-tag (Supplementary Figure S4, 
online), which colocalized with the signal for the Golgi marker 
GM130 (Supplementary Figure S7, online). The signals were 
clearly higher in the cardiac muscle than that in the skeletal muscles 
(except diaphragm) (Figure 3b). Consistently, functionally glyco-
sylated α-DG became evident in nearly all cardiac muscle fibers as 
detected by IIH6 antibody (Figure 3a). The intensity of IIH6 signal 
reached near normal levels by western blots and the same size band 
of α-DG bound laminin as well, indicating its functionality.
Real-time PCR analysis of FKRP transgene and 
endogenous FKRP expression
To determine the amount of FKRP required for the restoration of 
functional glycosylation of α-DG, we measured the levels of FKRP 
transcript by real-time quantitative polymerase chain reaction 
(qPCR). Primers were designed for transcripts specific to endog-
enous FKRP and the FKRP transgene (Life Technologies, Applied 
Biosystems, Foster City, CA). The results showed that levels of wild-
type FKRP mRNA were higher in cardiac muscle and diaphragm, 
almost twofold greater than those in TA muscles. The mRNA lev-
els of mutant endogenous FKRP in the muscles were however con-
siderably lower than the levels of the wild-type diaphragm, heart 
and TA muscle (about 40, 60, and 60%, respectively) (Figure 6a). 
Interestingly, the levels of mRNA of the FKRP transgene were higher 
than that of the mutant endogenous FKRP in the diaphragm, but 
were lower in the heart and especially in the TA muscle (Figure 6a). 
The mRNA levels from the transgene were consistent with the levels 
of the vector-expressed FKRP protein in the three muscles detected 
by both immunofluorescence staining and western blots.
FKRP expression in kidney, liver, and toxicity 
assessment
We also examined FKRP transgene expression and levels of 
functionally glycosylated α-DG in the liver and kidney not 
Figure 5 Grip force measurement and serum tests. (a) Hindlimb and (b) forelimb grip force measurement. Grip force strength is normalized for 
body weight. P448L, P448L mutant mice without AAV treatment. AAV-treated, P448L mutant mice treated with AAV9-FKRP. WT, C57BL/6 normal 
control. (c) Serum tests. *Significant difference was observed between the AAV-treated FKRP mutant mice when compared with untreated FKRP 
mutant mice (n = 5, two-tailed t-test, *P ≤ 0.05). CK (creatine kinase, kU/l), creatinine (mg/l), urea nitrogen (mg/ml), total bilirubin (mg/l), alanine 
transaminase (ALT) (U/dl), alkaline phosphatase (ALP) (U/dl) and γ-glutamyltransferase (GGT) (U/l).
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Figure 6 Detection of FKRP transcript in muscles and protein in 
liver and kidney. (a) Quantitative PCR for the detection of endogenous 
and transgene FKRP expression. P448L FKRP, endogenous mutant FKRP; 
WTFKRP, normal FKRP expressed in C57BL/6 mice; transgene, AAV9-
FKRP vector-expressed FKRP. The Copies (normalized) indicates the rela-
tive copy number to the control GAPDH. n = 3. (b) Detection of FKRP 
in liver and kidney from AAV9-FKRP-treated mouse. (c) α-DG and β-DG 
detection in liver and kidney by western blots. K, kidney; L, liver; P448L 
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known to be implicated in the pathophysiology of the dystro-
glycanopathies. Previous studies have reported high efficiency 
of AAV9 gene transfer to the hepatocytes. However, we detected 
FKRP expressed only in a small proportion (less than 5%) of 
the hepatocytes by immunohistochemistry (Figure 6b). No 
FKRP was clearly detected by immunohistochemistry in the 
kidney. Western blot analysis revealed that FKRP expression 
was nearly undetectable in both of these organs. Functionally 
glycosylated α-DG was not detected in the livers of all normal 
control mice, untreated and AAV9-FKRP treated FKRP mutant 
mice by western blot with IIH6 antibody (Figure 6c). In con-
trast, glycosylated α-DG was detected in the kidney of normal 
mice, but clearly reduced in the untreated FKRP mutant mice, 
suggesting that defects in FKRP affect the functional glycosyl-
ation of α-DG. The levels of expression increased considerably 
in the AAV9-FKRP treated mutant mice although this was still 
lower than that in normal mice (Figure 6c). These results sug-
gest that a small amount expression of vector-derived FKRP, 
although not clearly detectable, might have functional sig-
nificance. Interestingly, β-DG was clearly detected in the liver 
tissues, but barely detectable in the kidneys of the mice from 
all groups (normal mice, AAV-treated, and untreated FKRP 
mutant mice) despite the same quantity loading (40 µg) of tissue 
sample (Figure 6c). One possible explanation is that the kidney 
expresses very low levels of DG protein, but a large proportion of 
α-DG was functionally glycosylated. In contrast, there are high 
levels of DG expression with little functional glycosylation in 
the liver. However, differential glycosylation of α-DG between 
the two organs could not be excluded. Serum tests showed that 
levels of alkaline phosphatase, creatinine, BUN, and ALT, indi-
cators for liver and kidney functions, were all comparable with 
those seen in normal C57BL/6 mice. No significant difference 
in body weight was observed between the AAV9-FKRP treated 
and untreated groups during the period of treatment after the 
i.p. delivery of the AAV9-FKRP (Supplementary Figure S8, 
online).
DIsCUssION
AAV-mediated gene therapy has been shown to be highly effec-
tive in correcting disease phenotypes of several animal models of 
muscular dystrophies with deficiencies in dystrophin and the sar-
coglycans.17,19,23 In general AAV is amongst one of the safest and 
least immunogenic gene vectors, although cellular immunity to 
the vector34 or novel transgene product35 has been reported in a 
few cases from numerous human gene therapy clinical studies. In 
this study, we chose the AAV9 serotype as we recently reported 
that AAV9 produced high levels of transgene expression in skele-
tal muscles with a higher tropism in cardiac muscle.36 The chicken 
β-actin promoter coupled with the CMV enhancer was used for 
effective transgene expression which might be further enhanced 
by codon-optimization of the cDNA (Supplementary Figure S1, 
online). We now show for the first time that this vector is able to 
effectively and persistently render the expression of FKRP in the 
mouse model of FKRP P448L mutation found in patients. This 
leads to the restoration of functionally glycosylated α-DG in all 
skeletal and cardiac muscles with significant improvement in 
muscle pathology and function, providing direct evidence for the 
therapeutic potential of AAV9-mediated gene therapy for FKRP-
related muscular dystrophies. These results also further confirm 
that FKRP is essential for functional glycosylation of α-DG and 
FKRP mutations are the causal factors for the LGMD2I.
Cardiomyopathy is a common feature in FKRP-related mus-
cular dystrophies and becomes an increasingly important consid-
eration for treatment development. AAV9 with higher tropism 
to cardiac muscle over several other AAV serotypes could be the 
choice for treating FKRP-related cardiomyopathy.20,21 This is now 
further confirmed in the current study. FKRP expression both at 
the mRNA and protein levels is higher in the cardiac muscle than 
in all skeletal muscles examined in our study. Consequently, this 
resulted in the highest expression of functionally glycosylated 
α-DG, reaching the levels similar to that in normal cardiac mus-
cle. While we could not verify the therapeutic effect on cardiac 
muscle functions due to mild pathological changes in the cardiac 
functions within the age group of the model mouse, one would 
expect a significant functional rescue if similar efficiency in FKRP 
expression and functional glycosylation of α-DG is achieved in 
hearts with cardiomyopathy due to FKRP mutations. A long-term 
therapeutic effect of AAV9-mediated FKRP delivery to the cardiac 
muscle is being currently conducted.
There are potential disadvantages of using AAV9 for systemic 
gene therapy for muscular dystrophy. One is the reported high 
levels of transduction of transgene in liver. Since FKRP muta-
tions do not apparently affect liver function and FKRP func-
tion in organs other than muscles remains poorly understood, 
unwanted overexpression of FKRP in the liver might pose risk 
of side effects. However, this concern could be overcome by the 
use of recombinant AAV9 vector coupled with tissue specific 
promoter and microRNA-targeted transgene mRNA degrada-
tion.36 In the current study, although we did not use muscle- 
and heart-specific promoter in AAV9 for FKRP expression, we 
detected no broad expression of FKRP in the liver, but only in a 
small proportion (<5%) of the hepatocytes with levels no higher 
than that in muscles. The limited expression of FKRP protein to a 
small proportion of hepatocytes is apparently not consistent with 
some early reports that AAV9 displayed homogenous transgene 
expression under the control of CMV-CB promoter in liver. One 
possible explanation is the nature of the transprotein expressed 
by the AAV vector. In our previous mini-dystrophin gene ther-
apy study, the AAV9 vector with CMV promoter produced high 
levels of dystrophin expression in muscle, but very low levels 
in the liver, despite the presence of high copy number of viral 
DNA. Several other possible explanations have been proposed to 
explain the variation in expression of transgenes in liver, includ-
ing route-dependent and gender-dependent variation in levels of 
transgene expression.37
Importantly, the expression of FKRP did not induce the expres-
sion of functional glycosylation of α-DG in the liver. Furthermore, 
no clear liver toxicity was observed from serum enzyme tests and 
histology. Although FKRP expression was minimal in the kidney 
which expresses functionally glycosylated α-DG,38 this amount 
could still be beneficial as the treated kidney improved the lower 
levels of glycosylation of α-DG in mutant mice towards normal 
levels. These results suggest that AAV9 together with muscle spe-
cific promoter could constitute an effective, largely muscle specific 
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vector system with preference for cardiac muscle to treat FKRP-
related dystroglycanopathies with cardiomyopathy.
O-Manno-glycosylation of α-DG is essential for its interac-
tion with extracellular ligands and mutations in nine genes have 
been known to disrupt glycosylation pathway for α-DG.6 The 
involvement of FKRP in the functional glycosylation of α-DG 
is evidenced by the hypoglycosylation of α-DG in LGMD2I, 
Walker–Warburg syndrome and MDC1C with FKRP mutations 
and in our newly developed FKRP mutant mice.31 However, the 
roles of FKRP on the process of glycosylation of α-DG have yet 
to be defined. It is also possible that FKRP might be involved in 
glycosylation of other glycoproteins. Therefore, it is important to 
determine whether overexpression of FKRP via AAV-mediated 
gene therapy might cause unforeseeable consequences. This would 
be especially relevant as most mutated FKRP genes still express at 
least partially functional FKRP proteins judged by the presence 
of variable amount of glycosylated α-DG in muscles. Our results 
from the current study showed that expression of the FKRP trans-
gene restored the functional glycosylated α-DG with significant 
improvement in muscle pathology and function. Individual mus-
cle fibers expressing extremely high levels of FKRP, with signals 
covering entire cytoplasmic region, were histologically normal in 
size and shape without any sign of degeneration. The presence of 
such fibers therefore suggests that overexpression of FKRP within 
certain levels is unlikely to produce significant cellular toxicity. 
These results also support the view that FKRP might have very 
limited function outside the glycosylation of α-DG after birth, 
and would be consistent with our initial results from a glyco-pro-
teomic study. This study used LTQ-XL Orbitrap mass spectrom-
eter to analyze the expression and glycosylation patterns of nearly 
900 glycoproteins in skeletal muscles of FKRP mutant mouse 
models and showed that no glycoproteins from the muscle tissues, 
except α-DG, were apparently altered in size by the lack of expres-
sion of functional FKRP (manuscript in preparation). These data 
together suggest that α-DG is the principle target of sugar modifi-
cations by FKRP, which may explain the lack of side effects found 
after overexpression of FKRP in the P448L mice.
One potential difficulty in assessing the function of FKRP is 
the inability to detect endogenous FKRP protein despite the fact 
that exogenous FKRP proteins can be reliably detected by immu-
nohistochemistry and western blots in both cell culture and in 
vivo in animal models after gene transfer with either naked plas-
mid32 or AAV viral vectors. The reason(s) behind this apparent 
discrepancy in detecting endogenous and exogenous FKRPs is not 
understood. One possibility is that endogenous FKRP is expressed 
at very low levels, beyond sensitivity of the detection systems. To 
assess the levels of AAV-mediated FKRP expression relative to 
the endogenous FKRP expression, we therefore measured mRNA 
levels of both FKRPs in the treated mice in comparison with nor-
mal mice by qPCR. We would expect high levels of exogenous 
FKRP transcript judging from the abundant exogenous FKRP 
protein. However, it was rather surprising to see that the amount 
of endogenous mutant FKRP transcripts is roughly the same as 
that of vector-derived transcripts in the diaphragm, and is actu-
ally higher in heart and TA muscle (approximately twofold) than 
that of vector-derived transcripts in the same muscles. This result 
might be partly due to the use of codon-optimized cDNA with 
higher efficiency in translation. One other possibility is that main-
taining normal levels of functional glycosylated α-DG requires 
only very limited amount of FKRP protein. This however would 
be inconsistent with the requirement of considerably high levels of 
vector-derived FKRP protein for the restoration of functional gly-
cosylation observed in muscles in this study. It is clear that novel 
approaches are required to answer this apparent conundrum.
MATeRIAls AND MeTHODs
Antibodies. The following primary antibodies were used: FKRP-829 
(FKRPSTEM) rabbit polyclonal antibody raised against the stem region 
(amino acid residues 29–130) of the mouse FKRP;1 anti-GM130-FITC 
monoclonal antibody (BD Biosciences, San Jose, CA); rabbit anti-GM130 
polyclonal antibody (EMD Chemicals, Darmstadt, Germany); rabbit 
anti-c-Myc polyclonal antibody (Sigma, Saint Louis, MO); 9E10 mono-
clonal anti-Myc antibody produced from hybridoma cells (NIH DSHB, 
Iowa City, IA); IIH6C4 (IIH6) monoclonal antibody against functionally 
glycosylated α-DG (Millipore, Temecula, CA); mouse anti-β-DG mono-
clonal antibody (DSHB, Iowa City, IA); Monoclonal anti-β-actin (Sigma, 
St. Louis, MO).
AAV9-CMV-CB-FKRP vector construction and rAAV production. The full 
length of 1482 bp mouse FKRP was codon optimized for high expression 
(GeneArt, Life Technologies). The sequence coding for the ten amino acid 
Myc-tag was linked to the C-terminal of the FKRP coding region and 
Kozak sequence was placed in front of the N-terminus of the FKRP coding 
sequence (Supplementary Figure S1, online). The synthetic fragment was 
cloned into pMK-RQ (KanR) using Sfil and Sfil sites. The resulting vector 
was named FKRP-PMK-RQ (GeneArt, Life Technologies). The NotI-SalI 
fragment of codon-optimized human-FKRP-Myc was cohesively ligated 
to the NotI and SalI restriction enzyme sites on AAV plasmid containing 
CMV-CB promoter36 and the final construct was named pXX-CB-FKRP-
Myc. The recombinant AAV vectors were produced by following the 
three-plasmid cotransfection method.39 The titers of viral vector genome 
numbers were determined by the viral DNA dot blot method. The concen-
tration of viral vectors was kept in the range of 2 × 1012 to 5 × 1012 vector 
genomes/ml and stored at −80 °C for future use. The final viral vector was 
named AAV9-CMV-CB-FKRP-myc (AAV9-FKRP in short).
C2C12 cell culture and AAV delivery. C2C12 myoblasts were cultured in 
DMEM supplemented with 10% fetal bovine serum and 4 mmol/l l-glu-
tamine. Cells were grown to 70–80% confluence and then infected with 
AAV9-FKRP 5 × 1010 viral particles per ml of culture media. Cells were cul-
tured either for 48 hours or for further 72 hours in differentiation media 
(4% serum only) and then prepared for examination. Cells grown on eight-
well culture slides were prepared for immunocytochemistry and in six-well 
plates for western blot analysis. All culture media and reagents were pur-
chased from Invitrogen/Gibco Life Sciences.
Animals and AAV vector delivery methods. FKRP P448L mutation has 
been associated with MDC1C.2,30 Mutant mice were generated by inGe-
nious Targeting Laboratory (Stony Brook, NY). The targeting vector was 
engineered with a 1343C>T point mutation, resulting in an amino acid 
change from proline to leucine at position 448. The homozygote mutant 
mice containing a Neo cassette showed severe muscular dystrophy with 
brain and eye involvement and were unable to breed.31 The Neo cassette 
was therefore removed via crossbreeding with C57BL/6 FLP mice (inGe-
nious Targeting Laboratory, Inc.) to create homozygote Fkrpp448L Neo- 
mice. This strain of homozygote mutant mice (referred as P448L mutant) 
has moderate skeletal muscle dystrophy essentially the same as the FKRP 
P448L Neo+ homozygotes reported previously,31 but lacks a clear defect in 
the central nervous system and shows normal breeding activity with near 
normal life span. There was no obvious pathology in cardiac muscle in the 
young adult mice. The homozygote FKRPP448L Neo-mice were therefore 
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used in this study. C57BL/6 wild-type mice aged 4 weeks were used as con-
trols. Experiments were approved by the Institutional Animal Care and 
Use Committee, Carolinas Medical Center. P448L mutants at the age of 
3–4 weeks were administrated with AAV9-FKRP 5 × 1011 viral particles via 
single i.p. injection. Treated and control mice were euthanized 4 months 
after the AAV treatment. Blood and muscle samples were collected and 
stored for further analysis.
Histological analysis and fiber size determination. Skeletal and car-
diac muscles were snapped frozen in liquid nitrogen chilled isopentane. 
Sections of 5 µm thickness were cut from the frozen tissues and stained 
with hematoxylin and eosin (H&E). Sections were then examined using an 
Olympus BX51 microscope.
Fiber size of TA and quadriceps was determined using the MetaMorph 
Basic Offline software. H&E images with original 20× magnification 
were subjected to Arithmetic processing to remove background noise 
and clearly identify muscle fibers. Processed images were then used to 
outline individual fibers as well as remove all other color from the image. 
This results in each fiber being outlined in black with a white interior 
and ensures that every fiber was accounted for in the final analysis. The 
outlined image was then calibrated appropriately using the software’s 
calibrate distances tool. An image that was 1360 × 1040 pixels with a 20× 
magnification is ~0.4988 µm/pixel. Once calibrated the fibers were then 
threshold by excluding dark objects. Using the integrated morphometry 
analysis tool the equivalent radius of each fiber was determined and the 
data exported into excel for analysis. Fibers contacting the edge of the 
image were excluded from data analysis. The diameter of each fiber was 
calculated from the equivalent radius. During image processing the size 
of the image, pixel height, and width, were kept the same. Fibers with 
diameter smaller than 30 µm and larger than 80 µm were selected as 
subgroups as they were rarely detected in normal muscles.
Immunohistochemical analysis. For the detection of FKRP, Myc-tag, and 
Golgi marker GM130, cells and frozen sections were first fixed with 4% 
PFA for 15 minutes followed by incubation with 0.5% Triton X-100 for 
5 minutes. The sections were then blocked with 8% bovine serum albu-
min and 10% fetal bovine serum diluted in phosphate-buffered saline for 
30 minutes followed by incubation with primary antibody at room tem-
perature. FKRP was detected with the FKRPSTEM antibody at 1:2,500 
dilutions for 2 hours. The cis-Golgi marker GM130 was detected with 
fluorescence-labeled GM130 at 1:50 dilution for 6 hours. Myc-tag was 
detected with monoclonal antibody 9E10 at 1:15 dilution for 2 hours and 
polyclonal rabbit anti-Myc at 1:250 dilutions for 2 hours. Functionally gly-
cosylated α-DG was detected with IIH6 as described previously.31 The pri-
mary antibodies were visualized with AlexaFluor488 or 594-conjugated 
goat anti-mouse or rabbit IgGs at 1:500 dilutions in phosphate-buffered 
saline for 1 hour. All antibodies were diluted in phosphate-buffered saline 
containing 10% fetal bovine serum and all steps were performed at room 
temperature unless specified. Immunofluorescence results were visualized 
using an Olympus BX51/BX52 fluorescence microscope and images were 
captured using the Olympus DP70 Digital Camera System (OPELCO, 
Dulles, VA).
Protein extraction, western blot analysis, and laminin overlay assay. 
Protein extraction and Western blot analysis were performed as reported 
previously.31 A laminin overlay assay was performed as reported previ-
ously.31,40 Laminin overlay assay demonstrates the ability of functionally 
glycosylated α-DG to bind the laminin, thus the functionality of α-DG.
Quantitative PCR analysis. RNA was isolated using TRIzol reagent 
(Invitrogen, Carlsbad, CA) and reverse transcribed with iScript cDNA 
synthesis kit (Bio-Rad, Hercules, CA). Quantitative PCR was performed 
on an ABI Prism 7500 Fast Real-Time PCR System using TaqMan Probe-
Based Detection (Applied Biosystems, Foster City, CA). RNA samples 
were treated with RNase-free DNase before addition of Taqman Gene 
Expression Assays and Taqman Gene Expression Master Mix. All probes 
were custom designed from Applied Biosystems (the FKRP endogenous 
mutant assay ID is AIHR130; the FKRP transgene/optimized assay ID is 
AJ20SP0). GAPDH (assay ID is Mm03302249-g1) was used as an internal 
control. All reactions were performed in triplicates. Data were analyzed 
using RealTime StatMiner, version 4.0 (Integromics, Philadelphia, PA).
Grip force test. Grip strength was assessed with a grip strength meter 
consisting of horizontal forelimb mesh and an angled hindlimb mesh 
(Columbus Instruments, Columbus, OH). Five successful forelimb and 
hindlimb strength measurements were recorded in 2 minutes. The maxi-
mum values of each day over a 5-day period were used for subsequent data 
analysis. Grip strength measurements were normalized to body weight and 
expressed as kilogram force.41,42
Statistical analysis. All the results were expressed as mean ± SEM and the 
data were analyzed using two-tailed “t” test. A P value of <0.05 was consid-
ered as the level of significance.
sUPPleMeNTARY MATeRIAl
Figure S1. Codon-optimized FKRP sequences for mammalian 
expression.
Figure S2. Co-localization of Myc-tag signal with GM130 in AAV9-
FKRP treated C2C12 myoblasts.
Figure S3. Detection of AAV9-mediated FKRP expression in TA 
muscles.
Figure S4. Co-localization of FKRP expression (a, b and d detected 
with FKRPSTEM antibody) and functionally glycosylated α-DG (c, e 
and f detected with IIH6 antibody).
Figure S5. Fiber size measurement.
Figure S6. Histological analysis of muscle tissues from control P448L 
mutant mice (left column) and AAV-FKRP treated P448L mutant mice 
(Right column).
Figure S7. Co-localization of GM130 and FKRP in cardiac muscle.
Figure S8. Body weight measurement.
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